Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.64 | 2.2 |
NAV | ₹134.06 | ₹100.44 |
Fund Started | 15 Feb 2007 | 25 Mar 1997 |
Fund Size | ₹18018.85 Cr | ₹1072.74 Cr |
Exit Load | Exit load for units in excess of 10% of the investment, 1% will be charged for redemption within 1 year. | Exit load of 1%, if redeemed within 30 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 32.12% | 26.58% |
3 Year | 21.09% | 25.59% |
5 Year | 22.35% | 24.49% |
1 Year
3 Year
5 Year
Equity | 98.71% | 99.31% |
Cash | 1.29% | 0.69% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
HDFC Bank Ltd. | 7.34% |
ICICI Bank Ltd. | 7.15% |
Infosys Ltd. | 6.33% |
Axis Bank Ltd. | 3.49% |
NTPC Ltd. | 3.13% |
Coforge Ltd. | 2.60% |
Mahindra & Mahindra Ltd. | 2.59% |
REC Ltd. | 2.58% |
Larsen & Toubro Ltd. | 2.44% |
Zomato Ltd. | 2.41% |
Name | Assets |
---|---|
HDFC Bank Ltd. | 7.21% |
Infosys Ltd. | 4.57% |
ICICI Bank Ltd. | 4.12% |
Dr. Reddy's Laboratories Ltd. | 3.14% |
State Bank of India | 2.74% |
NTPC Ltd. | 2.64% |
REC Ltd. | 2.49% |
Tech Mahindra Ltd. | 2.23% |
Amber Enterprises India Ltd. | 2.16% |
Suven Pharmaceuticals Ltd. | 2.07% |
Name | Amit Ganatra | Satish Ramanathan |
Start Date | 01 Sep 2022 | 01 Oct 2024 |
Name
Start Date
Description | The scheme seeks to generate capital appreciation by investing predominantly in Equity and Equity Related Instruments through contrarian investing. | The scheme aims to provide long term capital growth by investing primarily in a well-diversified portfolio of undervalued securities. |
Launch Date | 15 Feb 2007 | 25 Mar 1997 |
Description
Launch Date